Release Date: July 31, 2025
Expiration Date: July 31, 2026
Activity Overview
Recent findings indicate that hypercortisolism can be an underlying contributor to difficult-to-control type 2 diabetes (T2D), and it may occur with lower cortisol levels than noted in overt Cushing syndrome. In this program, expert faculty discuss new perspectives on the prevalence of mild hypercortisolism in T2D, appropriate ways to diagnose it, and recently presented data on medical management.
Target Audience
This educational curriculum is directed towards endocrinologists, diabetologists, primary care physicians, and other health care professionals involved in the diagnosis and management of hypercortisolism in patients with T2D, including, but not limited to, nurses, nurse practitioners, physician assistants, and registered nurses.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the role of hypercortisolism in the development of type 2 diabetes
- Identify risk factors for hypercortisolism in patients with type 2 diabetes
- Apply screening recommendations to identify hypercortisolism in patients with type 2 diabetes
- Assess clinical trial data for therapies for hypercortisolism
Richard E. Pratley, MD
AdventHealth Samuel E. Crockett Chair in Diabetes Research
Medical Director, AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead, AdventHealth Translational Research Institute
Adjunct Professor of Medicine, Johns Hopkins University School of Medicine
Orlando, FL
Disclosures: Research/Grant Support: Biomea Fusion, Carmot Therapeutics, Dompe, Eli Lilly and Company, Endogenex, Fractyl, Novo Nordisk, Sanofi; Speaker’s Bureau: Lilly USA, Novo Nordisk; Consultant: AbbVie, Altanine, Amgen, AstraZeneca, Bayer AG, Bayer HealthCare, Boehringer Ingelheim, Corcept Therapeutics, Eli Lilly and Company, Endogenex, F. Hoffmann-La Roche, Gasherbrum Bio, Genprex, Getz Pharma, Hanmi, Intas, Lexicon, Lilly USA, Novo Nordisk, Pfizer, Regeneron, Scholar Rock, Sun.
Vivian Fonseca, MD, FRCP
Professor of Medicine and Pharmacology
Assistant Dean for Clinical Research
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
John Deming Department of Medicine
Tulane University School of Medicine
Disclosures: Grant Support: Novo Nordisk; Consultant: Abbot, Corcept, Eli Lilly and Company, Regeneron; Stock Options: Abbott, Amgen, BRAVO4HEALTH, Mellitus Health.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
